Zobrazeno 1 - 10
of 813
pro vyhledávání: '"J, Lekakis"'
Publikováno v:
Clinical Medicine Insights: Case Reports, Vol 14 (2021)
SARS-CoV-2 emerged as a worldwide pandemic in late 2019 and initially was described as a primary respiratory illness. The clinical manifestations of COVID-19 are now known to encompass nearly all organ systems, including the central nervous system. W
Externí odkaz:
https://doaj.org/article/bfb92433997c4ff59734f6bafc39d744
Autor:
Lazaros J. Lekakis, Craig H. Moskowitz
Publikováno v:
HemaSphere, Vol 3, Iss 6, p e295 (2019)
Abstract. For many years now and based on the results of the PARMA trial, relapsed Diffuse Large B-cell Lymphoma (DLBCL) is treated with salvage combination cytotoxic chemotherapy (most often platinum-based) followed by high dose myeloablative chemot
Externí odkaz:
https://doaj.org/article/c1296e188b6947efac5de1f72da09f2c
Autor:
Nathalie Scholler, Regis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon
Publikováno v:
Nature Medicine. 28:1872-1882
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b443f4e993bc46949e19a3f481960b3
https://doi.org/10.1038/s41591-022-01916-x
https://doi.org/10.1038/s41591-022-01916-x
Autor:
G. Andrikopoulos, D. Terentes-Printzios, S. Tzeis, C. Vlachopoulos, C. Varounis, N. Nikas, J. Lekakis, D. Stakos, S. Lymperi, D. Symeonidis, D. Chrissos, C. Kyrpizidis, D. Alexopoulos, S. Zombolos, S. Foussas, Α. Κranidis, Κ. Oikonomou, V. Vasilikos, P. Andronikos, Α. Dermitzakis, D. Richter, N. Fragakis, I. Styliadis, S. Mavridis, C. Stefanadis, P. Vardas
Publikováno v:
Hellenic Journal of Cardiology, Vol 57, Iss 3, Pp 157-166 (2016)
Introduction: In view of recent therapeutic breakthroughs in acute coronary syndromes (ACS) and essential demographic and socioeconomic changes in Greece, we conducted the prospective, multi-center, nationwide PHAETHON study (An Epidemiological Cohor
Externí odkaz:
https://doaj.org/article/2d8f7709b9194499b14c918c46d744ae
Autor:
Vijaya Raj Bhatt, Stephanie J. Lee, Jaime M. Preussler, Gerhard C. Hildebrandt, Tao Wang, Monzr M. Al Malki, Amer Beitinjaneh, Dipenkumar Modi, Margaret L. MacMillan, Lazaros J. Lekakis, Sherif M. Badawy, Akshay Sharma, Siddhartha Ganguly, Carrie L. Kitko, Hemant S. Murthy, Richard T. Maziarz, Stephen R. Spellman, Karen Chen, Mukta Arora, Betty K. Hamilton, Joseph A. Pidala, Hongtao Liu
Publikováno v:
Transplantation and Cellular Therapy. 28:34-42
The effect of chronic graft-versus-host disease (cGVHD) on the risk of nonrelapse mortality (NRM) and relapse has not been specifically studied in older adults, who are increasingly undergoing allogeneic hematopoietic cell transplantation (alloHCT) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07b7cfe24d5c9b1b6bd8b982847e8141
https://doi.org/10.1016/j.jtct.2021.10.002
https://doi.org/10.1016/j.jtct.2021.10.002
Autor:
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, marcos DeLima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Navneet S Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher S Strouse, Sherif M. Badawy, Samer AI Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H Vesole, Cindy H Lee, Attaphol Pawarode, Usama Gergis, Kevin Charles Miller, Leona A Holmberg, Aimaz Afrough, Melhem M Solh, Pashna Munshi, Taiga Nishihori, Larry D. Anderson, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H Qazilbash, Nina Shah, Shaji K Kumar, Saad Z. Usmani
Publikováno v:
Blood Advances.
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f8a2d8b50b1819f401bd7620962bbde
https://doi.org/10.1182/bloodadvances.2022009138
https://doi.org/10.1182/bloodadvances.2022009138
Autor:
Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M Reagan, Patrick Joseph Stiff, Ian W. Flinn, Umar Farooq, Andre Goy, Peter McSweeney, Javier Munoz, Tanya Siddiqi, Julio C. Chavez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J. Kim, Yan Zheng, Frederick L. Locke
Publikováno v:
Blood.
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbb77f450498235b04589f19745bd5b7
https://doi.org/10.1182/blood.2022018893
https://doi.org/10.1182/blood.2022018893
Autor:
Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Aravind Ramakrishnan, Yiyun Zhang, Yanqing Hu, Vijay G R Peddareddigari, Nushmia Z Khokhar, Robert W Chen, Silvia Basilico, Meera Raymond, Frederick Arce Vargas, Kevin Duffy, Wolfram Brugger, Maeve O'Reilly, Leigh Wood, David Linch, Karl S Peggs, Carlos Bachier, Elizabeth Lihua Budde, Connie Lee Batlevi, Nancy L. Bartlett, David Irvine, Eleni Tholouli, Wendy Osborne, Kirit M Ardeshna, Martin Pule
Publikováno v:
Blood.
Relapse following CD19-directed chimeric antigen receptor T-cells (CAR-T) for relapsed/refractory large B-cell lymphoma (r/r LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multi-antigen targeting and PD-1 blockade are rational approa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff6b7808eb57a7f42b72ce6392acc75e
https://doi.org/10.1182/blood.2022018598
https://doi.org/10.1182/blood.2022018598
Autor:
Eleftheria J. Lekakis
Publikováno v:
The Routledge Companion to Advertising and Promotional Culture ISBN: 9781003124870
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2f25dc09d9ff7c320993be0a67ec160
https://doi.org/10.4324/9781003124870-30
https://doi.org/10.4324/9781003124870-30
